AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic bre...
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
About this item
Full title
Author / Creator
Abu-Khalaf, Maysa M. , Alex Hodge, K. , Hatzis, Christos , Baldelli, Elisa , El Gazzah, Emna , Valdes, Frances , Sikov, William M. , Mita, Monica M. , Denduluri, Neelima , Murphy, Rita , Zelterman, Daniel , Liotta, Lance , Dunetz, Bryant , Dunetz, Rick , Petricoin, Emanuel F. and Pierobon, Mariaelena
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Endocrine therapy (ET) in combination with CDK4/6 inhibition is routinely used as first-line treatment for HR+/HER2− metastatic breast cancer (MBC) patients. However, 30–40% of patients quickly develop disease progression. In this open-label multicenter clinical trial, we utilized a hypothesis-driven protein/phosphoprotein-based approach to identif...
Alternative Titles
Full title
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c34fa79216b44a448f600ad8e158ac17
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c34fa79216b44a448f600ad8e158ac17
Other Identifiers
ISSN
2397-768X
E-ISSN
2397-768X
DOI
10.1038/s41698-023-00360-5
